Galectin Therapeutics Inc Market Cap ($316.67 Million)
Market Cap & Net Worth: Galectin Therapeutics Inc (GALT)
Galectin Therapeutics Inc market cap. Galectin Therapeutics Inc (NASDAQ:GALT) has a market capitalization of $316.67 Million ($316.67 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #14256 globally and #3422 in its home market, demonstrating a 5.02% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Galectin Therapeutics Inc's stock price $3.35 by its total outstanding shares 100849644 (100.85 Million). Also see Galectin Therapeutics Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Galectin Therapeutics Inc Market Cap History (2015–2026)
Galectin Therapeutics Inc market cap history from 2015 to 2026. Data shows growth from $165.39 Million to $337.85 Million (1.00% CAGR). Check current stock price of Galectin Therapeutics Inc for real-time trading data and today's change.
Index Memberships
Galectin Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.01% | #379 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1395 of 3165 |
Weight: Galectin Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Galectin Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Galectin Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Galectin Therapeutics Inc (GALT) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of GALT by Market Capitalization
Companies near Galectin Therapeutics Inc in the global market cap rankings as of November 4, 2026. Also see Galectin Therapeutics Inc (GALT) total assets for a full breakdown of the balance sheet.
Key companies related to Galectin Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Galectin Therapeutics Inc (2015–2026)
Market capitalization of Galectin Therapeutics Inc from 2015 to today. Between 2015 and today, Galectin Therapeutics Inc's market cap moved from $165.39 Million to $ 337.85 Million, with a yearly change of 1.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $337.85 Million | -19.47% |
| 2025 | $419.53 Million | +222.48% |
| 2024 | $130.10 Million | -22.29% |
| 2023 | $167.41 Million | +46.90% |
| 2022 | $113.96 Million | -45.41% |
| 2021 | $208.76 Million | -7.59% |
| 2020 | $225.90 Million | -21.68% |
| 2019 | $288.43 Million | -16.62% |
| 2018 | $345.91 Million | +2.69% |
| 2017 | $336.84 Million | +240.89% |
| 2016 | $98.81 Million | -40.26% |
| 2015 | $165.39 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Galectin Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $316.67 Million USD |
| MoneyControl | $316.67 Million USD |
| MarketWatch | $316.67 Million USD |
| marketcap.company | $316.67 Million USD |
| Reuters | $316.67 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Galectin Therapeutics Inc
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhos… Read more